Northland Securities reiterated their buy rating on shares of ImmuPharma (LON:IMM) in a report issued on Thursday. The firm currently has a GBX 181 ($2.45) price objective on the stock.

IMM has been the topic of a number of other research reports. FinnCap assumed coverage on shares of ImmuPharma in a research note on Tuesday, December 12th. They set a buy rating and a GBX 237 ($3.21) price target on the stock. Northland Capital Partners restated a buy rating and set a GBX 181 ($2.45) price target on shares of ImmuPharma in a research note on Thursday, September 21st.

Shares of ImmuPharma (LON IMM) traded up GBX 8.50 ($0.12) during trading on Thursday, reaching GBX 177 ($2.40). 1,569,823 shares of the company’s stock were exchanged, compared to its average volume of 519,298. ImmuPharma has a twelve month low of GBX 44 ($0.60) and a twelve month high of GBX 193.74 ($2.63). The firm has a market cap of $229.51 and a price-to-earnings ratio of -4,425.00.

ILLEGAL ACTIVITY WARNING: “ImmuPharma (IMM) Rating Reiterated by Northland Securities” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at

ImmuPharma Company Profile

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with's FREE daily email newsletter.